166 related articles for article (PubMed ID: 21540864)
1. Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches.
Lehmann-Che J; Amira-Bouhidel F; Turpin E; Antoine M; Soliman H; Legres L; Bocquet C; Bernoud R; Flandre E; Varna M; de Roquancourt A; Plassa LF; Giacchetti S; Espié M; de Bazelaire C; Cahen-Doidy L; Bourstyn E; Janin A; de Thé H; Bertheau P
Br J Cancer; 2011 May; 104(11):1739-46. PubMed ID: 21540864
[TBL] [Abstract][Full Text] [Related]
2. Comparing breast biomarker status between routine immunohistochemistry and FISH studies and Oncotype DX testing, a study of 610 cases.
Neely C; You S; Mendoza PM; Aneja R; Sahin AA; Li X
Breast J; 2018 Nov; 24(6):889-893. PubMed ID: 30230095
[TBL] [Abstract][Full Text] [Related]
3. Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases.
Zoppoli G; Garuti A; Cirmena G; di Cantogno LV; Botta C; Gallo M; Ferraioli D; Carminati E; Baccini P; Curto M; Fregatti P; Isnaldi E; Lia M; Murialdo R; Friedman D; Sapino A; Ballestrero A
J Transl Med; 2017 May; 15(1):91. PubMed ID: 28460632
[TBL] [Abstract][Full Text] [Related]
4. Relative quantification of ERBB2 mRNA in invasive duct carcinoma of the breast: correlation with ERBB-2 protein expression and ERBB2 gene copy number.
Mrhalová M; Kodet R; Kalinová M; Hilská I
Pathol Res Pract; 2003; 199(7):453-61. PubMed ID: 14521261
[TBL] [Abstract][Full Text] [Related]
5. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M
Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295
[TBL] [Abstract][Full Text] [Related]
6. Monoplex LightCycler polymerase chain reaction quantitation of the HER2 gene for quality assurance of HER2/neu testing by immunohistochemistry and fluorescence in situ hybridization.
Layfield LJ; Willmore-Payne C; Isom G; Holden JA
Appl Immunohistochem Mol Morphol; 2008 Dec; 16(6):562-7. PubMed ID: 18948825
[TBL] [Abstract][Full Text] [Related]
7. Real-time RT-PCR analysis for evaluating the Her2/neu status in breast cancer.
Cuadros M; Talavera P; López FJ; García-Peréz I; Blanco A; Concha A
Pathobiology; 2010; 77(1):38-45. PubMed ID: 20185966
[TBL] [Abstract][Full Text] [Related]
8. Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients.
Riethdorf S; Hoegel B; John B; Ott G; Fritz P; Thon S; Loening T; Pantel K
J Cancer Res Clin Oncol; 2011 Feb; 137(2):261-9. PubMed ID: 20396915
[TBL] [Abstract][Full Text] [Related]
9. HER2 status in gastric cancer: a comparison of two novel in situ hybridization methods (IQ FISH and dual color SISH) and two immunohistochemistry methods (A0485 and HercepTest™).
Pala EE; Bayol U; Ozguzer A; Akman O
Pathol Res Pract; 2013 Sep; 209(9):548-54. PubMed ID: 23910175
[TBL] [Abstract][Full Text] [Related]
10. Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinoma.
Rosa FE; Silveira SM; Silveira CG; Bérgamo NA; Neto FA; Domingues MA; Soares FA; Caldeira JR; Rogatto SR
BMC Cancer; 2009 Mar; 9():90. PubMed ID: 19309522
[TBL] [Abstract][Full Text] [Related]
11. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists.
Dietel M; Ellis IO; Höfler H; Kreipe H; Moch H; Dankof A; Kölble K; Kristiansen G
Virchows Arch; 2007 Jul; 451(1):19-25. PubMed ID: 17562074
[TBL] [Abstract][Full Text] [Related]
12. Correlation of HER2 gene amplification with immunohistochemistry in breast cancer as determined by a novel monoplex polymerase chain reaction assay.
Willmore C; Holden JA; Layfield LJ
Appl Immunohistochem Mol Morphol; 2005 Dec; 13(4):333-41. PubMed ID: 16280662
[TBL] [Abstract][Full Text] [Related]
13. Quantitative RT-PCR assay of HER2 mRNA expression in formalin-fixed and paraffin-embedded breast cancer tissues.
Park S; Wang HY; Kim S; Ahn S; Lee D; Cho Y; Park KH; Jung D; Kim SI; Lee H
Int J Clin Exp Pathol; 2014; 7(10):6752-9. PubMed ID: 25400755
[TBL] [Abstract][Full Text] [Related]
14. Detection of HER2 status in breast cancer: comparison of current methods with MLPA and real-time RT-PCR.
Pazhoomand R; Keyhani E; Banan M; Najmabadi H; Khodadadi F; Iraniparast A; Feiz F; Majidzadeh K; Bahman I; Moghadam FA; Sobhani AM; Muhammadnejad A; Abedini SS; Behjati F
Asian Pac J Cancer Prev; 2013; 14(12):7621-8. PubMed ID: 24460343
[TBL] [Abstract][Full Text] [Related]
15. Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome.
Bergqvist J; Ohd JF; Smeds J; Klaar S; Isola J; Nordgren H; Elmberger GP; Hellborg H; Bjohle J; Borg AL; Skoog L; Bergh J
Ann Oncol; 2007 May; 18(5):845-50. PubMed ID: 17351254
[TBL] [Abstract][Full Text] [Related]
16. Quantitative PCR--new diagnostic tool for quantifying specific mRNA and DNA molecules: HER2/neu DNA quantification with LightCycler real-time PCR in comparison with immunohistochemistry and fluorescence in situ hybridization.
Schlemmer BO; Sorensen BS; Overgaard J; Olsen KE; Gjerdrum LM; Nexo E
Scand J Clin Lab Invest; 2004; 64(5):511-22. PubMed ID: 15276916
[TBL] [Abstract][Full Text] [Related]
17. Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis.
Barberis M; Pellegrini C; Cannone M; Arizzi C; Coggi G; Bosari S
Am J Clin Pathol; 2008 Apr; 129(4):563-70. PubMed ID: 18343783
[TBL] [Abstract][Full Text] [Related]
18. Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.
Baehner FL; Achacoso N; Maddala T; Shak S; Quesenberry CP; Goldstein LC; Gown AM; Habel LA
J Clin Oncol; 2010 Oct; 28(28):4300-6. PubMed ID: 20697093
[TBL] [Abstract][Full Text] [Related]
19. Chromogenic in situ hybridisation testing for HER2 gene amplification in breast cancer produces highly reproducible results concordant with fluorescence in situ hybridisation and immunohistochemistry.
Bilous M; Morey A; Armes J; Cummings M; Francis G
Pathology; 2006 Apr; 38(2):120-4. PubMed ID: 16581651
[TBL] [Abstract][Full Text] [Related]
20. Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: a comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures.
López-Guerrero JA; Navarro S; Noguera R; Almenar S; Pellin A; Vázquez C; Llombart-Bosch A
Arkh Patol; 2003; 65(1):50-5. PubMed ID: 12669615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
